i think it's fair to say all the next-gen Ab platform companies have some similarity to MEDX it may be a stretch but the BMY data is another notch validating immunotherapy (specifically t-cell mediated) for cancer - something that imo bolster's MITI's overall approach (although the ALL data stands on its own)